0 0 A federal jury in California found that Kite Pharma – now part of Gilead Sciences – violated a patent from Memorial Sloan Kettering Cancer Center and licensed to BMS’ Juno Therapeutics in developing the CAR-T therapy Yescarta, approved in 2017.